BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30101% above fair value
$60.41−1.01 (-1.64%)
Close on Nov 20, 2026Market cap $11.69BP/E 159.0Yield –
BioMarin Pharmaceutical free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BioMarin Pharmaceutical's free cash flow for the twelve months ending Jun 30, 2026 was $738.18M, up 6.2% year over year. For fiscal 2025 it was $724.96M, up 48.7% from the year before. The highest annual figure on record is $724.96M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $724.96M | +48.7% |
| FY2024 | Dec 31, 2024 | $487.42M | +679.0% |
| FY2023 | Dec 31, 2023 | $62.57M | +13.9% |
| FY2022 | Dec 31, 2022 | $54.94M | -73.7% |
| FY2021 | Dec 31, 2021 | $208.96M | – |
| FY2020 | Dec 31, 2020 | -$28.95M | – |
| FY2019 | Dec 31, 2019 | -$96.76M | – |
| FY2018 | Dec 31, 2018 | -$124.41M | – |
| FY2017 | Dec 31, 2017 | -$207.98M | – |
| FY2016 | Dec 31, 2016 | -$376.22M | – |
| FY2015 | Dec 31, 2015 | -$447.15M | – |
| FY2014 | Dec 31, 2014 | -$187.48M | – |
| FY2013 | Dec 31, 2013 | -$122.53M | – |
| FY2012 | Dec 31, 2012 | -$26.96M | – |
| FY2011 | Dec 31, 2011 | -$54.80M | – |
| FY2010 | Dec 31, 2010 | -$30.72M | – |
| FY2009 | Dec 31, 2009 | -$2.07M | – |
| FY2008 | Dec 31, 2008 | -$65.54M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $139.29M | -17.2% |
| Q1 FY2026 | Mar 31, 2026 | $199.73M | +26.7% |
| Q4 FY2025 | Dec 31, 2025 | $58.92M | -64.5% |
| Q3 FY2025 | Sep 30, 2025 | $340.24M | +67.6% |
| Q2 FY2025 | Jun 30, 2025 | $168.17M | +72.6% |
| Q1 FY2025 | Mar 31, 2025 | $157.63M | +655.4% |
| Q4 FY2024 | Dec 31, 2024 | $166.10M | – |
| Q3 FY2024 | Sep 30, 2024 | $203.02M | +78.2% |
| Q2 FY2024 | Jun 30, 2024 | $97.44M | +101.0% |
| Q1 FY2024 | Mar 31, 2024 | $20.87M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.43M | – |
| Q3 FY2023 | Sep 30, 2023 | $113.91M | -11.7% |
| Q2 FY2023 | Jun 30, 2023 | $48.48M | +66.8% |
| Q1 FY2023 | Mar 31, 2023 | -$98.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.90M | – |
| Q3 FY2022 | Sep 30, 2022 | $129.02M | +64.7% |
| Q2 FY2022 | Jun 30, 2022 | $29.07M | -51.7% |
| Q1 FY2022 | Mar 31, 2022 | -$74.25M | -184.4% |
| Q4 FY2021 | Dec 31, 2021 | -$17.56M | – |
| Q3 FY2021 | Sep 30, 2021 | $78.33M | +12.5% |
| Q2 FY2021 | Jun 30, 2021 | $60.19M | +3721.3% |
| Q1 FY2021 | Mar 31, 2021 | $88.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$44.41M | -777.2% |
| Q3 FY2020 | Sep 30, 2020 | $69.64M | +86.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.58M | – |
| Q1 FY2020 | Mar 31, 2020 | -$55.75M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.56M | -10.1% |
| Q3 FY2019 | Sep 30, 2019 | $37.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$56.97M | – |
| Q1 FY2019 | Mar 31, 2019 | -$83.62M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.30M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$56.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$72.67M | – |
| Q4 FY2017 | Dec 31, 2017 | -$25.28M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.19M | – |
| Q2 FY2017 | Jun 30, 2017 | -$28.98M | – |
| Q1 FY2017 | Mar 31, 2017 | -$149.53M | – |
| Q4 FY2016 | Dec 31, 2016 | -$51.78M | – |
| Q3 FY2016 | Sep 30, 2016 | -$36.46M | – |
See a number that looks wrong?